Search Results
Your search for ,ITS matches 8694 pages
Showing 6751 - 6800ASCO Completes Prototype for CancerLinQ™, Marking First Demonstration of a 'Learning Health System' to Transform Cancer Care
ASCO has completed a prototype of CancerLinQ™, the Society’s groundbreaking health information technology initiative to achieve higher quality, higher value cancer care with better outcomes for patients. The prototype was shown on March 27 at the National Press Club in Washington, DC, during an...
ASCO President's Priorities Aim to Build Bridges to Advance Cancer Care
Recognizing the need for greater interconnectivity to accelerate cancer care advances, Sandra M. Swain, MD, FACP, current ASCO President and Medical Director of Washington Cancer Institute MedStar Washington Hospital Center, selected “Building Bridges to Conquer Cancer” as her presidential theme....
Disparities in Cancer Care: How A Deep South Community Overcame Them
Racial inequities were a daily observation for Edward E. Partridge, MD, growing up in Alabama during the civil rights era. When he became a physician, he saw that these disparities extended into his own field, gynecologic oncology. He decided to do something about it. Dr. Partridge recently...
Managing Female Reproductive Complications after Cancer Treatment in Children and Young Adults
Follow-up care for female patients treated for cancer as children, adolescents, or young adults should include assessment and management of the late effects that therapy may have on reproductive health, as detailed in updated guidelines from the Children’s Oncology Group. “It is important for...
Personal Testimonial: CAR-modified T Cells in Adults
Twelve adults with chronic lymphocytic leukemia (CLL) have been treated with CD19-targeted chimeric antigen receptor (CAR) T-cell therapy at the University of Pennsylvania in Philadelphia by Carl June, MD, Richard W. Vague Professor in Immunotherapy, and colleagues. These were all end-stage...
Preliminary Progress with Genetically Engineered T Cells in Treating Childhood ALL
Two small phase I studies at separate centers demonstrated encouraging results in the treatment of children with acute lymphoblastic leukemia (ALL) using reinfused autologous genetically engineered T cells. Results of both studies were presented at the Annual Meeting of the American Association for ...
Autologous Stem Cell Transplant Improves Survival in Transformed Follicular Lymphoma
As reported by the Canadian Blood and Marrow Transplant Group in Journal of Clinical Oncology,1 patients with transformed follicular lymphoma receiving autologous transplantation have improved survival outcomes compared with patients receiving rituximab (Rituxan)-containing chemotherapy alone....
University of Michigan Launches New Cardio-oncology Program
The University of Michigan Samuel and Jean Frankel Cardiovascular Center, working with specialists at the University of Michigan (U-M) Comprehensive Cancer Center, has launched Michigan’s first cardio-oncology clinic, a program designed to prevent or minimize heart damage caused by chemotherapy and ...
SIDEBAR: Critical Information on Radiation's Heart Effects
The paper by Darby et al provides extremely important information on quantitative estimates of the effect of radiotherapy on coronary events in women with breast cancer.1 The authors have determined a direct relationship between radiation dose and effects on the heart and provide strong evidence...
Tobacco Use in Cancer Patients: Often Overlooked but Critical to Address
One would hope that the importance of treatment for tobacco dependence would be well recognized as a cornerstone of standard care for cancer patients. However, a policy statement released by the American Association for Cancer Research (AACR) at its recent Annual Meeting revealed some surprising...
New Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitor Treatment
A new guideline for molecular testing to select lung cancer patients for treatment with epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors has been jointly developed by the College of American Pathologists, International Association for the Study ...
Novel Cancer Immunotherapy Set to Enter Clinical Trials
PDS Biotechnology Corporation has announced that its Investigational New Drug application for the novel cancer immunotherapy agent PDS0101 has been granted by the FDA, allowing the agent to be evaluated in human patients. PDS0101 is based on the company’s Versamune nanotechnology vaccine platform....
ASCO Announces New Conflict of Interest Policy
In April, ASCO released its updated conflict of interest policy in the development and presentation of scientific research and educational content. The revised policy is designed to increase transparency in financial relationships between individuals and health-care companies and impose new...
NCCN Clinical Practice Guidelines in Oncology: 2013 Updates
At the 18th Annual Conference of the National Comprehensive Cancer Network (NCCN), representatives of NCCN Guidelines panels presented two new sets of guidelines along with updates for several tumor types, summarized in this issue of The ASCO Post. New NCCN Guidelines for Survivorship “The...
On the Potential for Conflicts of Interest
In a recent issue of The ASCO Post, I counted 14 expert commentaries where the authority who wrote or was interviewed for the piece reported “no potential conflicts of interest.” I wondered how likely that was. We need to be clearer on the meaning of potential conflicts of interest. How often have...
Sequestration's Impact on Cancer Care
On March 1, the deficit-budget mechanism known as sequestration took effect, triggering $85 billion in across-the-board cuts to most federal agencies over the remaining 7 months in fiscal year 2013. The total federal deficit reduction budget under the Budget Control Act of 2011 calls for $1.2...
Black, Asian, and Younger Women at Increased Risk of PTSD after Diagnosis of Localized Breast Cancer
Nearly one-quarter of women in a large prospective study of racially diverse patients with stage I to III breast cancer reported symptoms consistent with posttraumatic stress disorder (PTSD), with increased risk of PTSD among black, Asian, and younger women. “These potential risk factors can be...
Innovator Award Won by Kenneth Tsai, MD, PhD, for Plan to Map Molecular Path to Skin Cancer
A proposal to examine the cellular journey from normal skin to precancerous lesion to skin cancer earned Kenneth Tsai, MD, PhD, the Sixth Annual Landon Foundation–AACR Innovator Award for Cancer Prevention Research at the American Association for Cancer Research (AACR) Annual Meeting, held recently ...
Innovative State Program Reduces Colorectal Cancer Disparities, Mortality Rates Among African American Patients
A study analyzing the impact of the Delaware Cancer Consortium, the state’s cancer control program, reports a 41% reduction in colorectal mortality rates for African Americans.1 The recently published study provided analysis on a novel design and approach used to eliminate colorectal cancer...
Focus on the Delaware Society for Clinical Oncology
Although the state of Delaware comprises just 2,489 square miles, giving it an area ranking of 49 out of 50 states, its small size gives its population of nearly 1 million an advantage many larger states do not have: ready access to local politicians to address complex issues such as improving...
SIDEBAR: How to Help
The American Cancer Society encourages all to assist in efforts to fight cancer by: Donating at cancer.org/fight Participating in a local Relay For Life or Making Strides Against Breast Cancer walk in their community Enrolling in its Cancer Prevention Study-3 to find better ways to prevent...
American Cancer Society Marks 100th Year Anniversary
The American Cancer Society announced the Society’s 100th birthday on May 22, 2013. Founded 100 years ago by 15 prominent physicians and business leaders in New York, the American Cancer Society, first known as the American Society for the Control of Cancer, launched the fight against a disease...
Making Prevention and Early Detection of Cancer a Priority
Conquering cancer has been the goal of Bert Vogelstein, MD, since he was a teenager in Baltimore. For more than 3 decades, Dr. Vogelstein, Co-Director of the Ludwig Center for Cancer Genetics and Therapeutics and Investigator of the Howard Hughes Medical Institute at Johns Hopkins Medical...
Ginger
The use of dietary supplements by cancer patients has risen significantly over the past 2 decades despite insufficient evidence of safety and effectiveness. Finding reliable sources of information about dietary supplements can be daunting. Patients typically rely on family, friends, and the...
American Association for Cancer Research CEO Recognized with Prestigious Award from Fox Chase Cancer Center
Margaret Foti, PhD, MD (hc), Chief Executive Officer of the American Association for Cancer Research (AACR), was honored with the 2013 Stanley P. Reimann Honor Award for her deep and far-reaching contributions to cancer science and medicine at a celebration hosted by Fox Chase Cancer Center, held...
Mayo Clinic Genomic Analysis Lends Insight to Prostate Cancer
Mayo Clinic researchers have used next-generation genomic analysis to determine that some of the more aggressive prostate cancer tumors have similar genetic origins, which may help in predicting cancer progression. The findings appeared online recently in the journal Cancer Research.1 Gleason...
SIDEBAR: Mara Mogensen Flagherty Lecture
The annual memorial lecture is named for a remarkable patient with cancer who was the “model of survivorship,” sharing her story and helping others cope with the disease. The talk always focuses on a psychosocial aspect of cancer. Since its inception, over 125,000 nurses have attended Mara Mogensen ...
Attention to Patient Concerns Leads to Customized Treatment and Improved Care, Explains Oncology Nurse Researcher
The Mara Mogensen Flagherty Lecture at this year’s 38th Annual Congress of the Oncology Nursing Society in Washington, DC, focused on the importance of listening to and acknowledging the individual stories of patients with cancer and survivors. Once they are adept at listening, clinicians need to...
EGFR Prevents Maturation of microRNAs under Hypoxic Conditions
The epidermal growth factor receptor (EGFR) sends signals that thwart the development of tumor-suppressing microRNAs under conditions of hypoxia, an international team led by scientists at The University of Texas MD Anderson Cancer Center discovered. The results were reported in an early online...
HIV Infection Does Not Adversely Affect Outcomes of Liver Transplantation for Hepatocellular Carcinoma
Liver transplantation for hepatocellular carcinoma is feasible for HIV-infected patients, with no differences in post-transplant survival or hepatocellular carcinoma recurrence rates compared with liver transplantation for hepatocellular carcinoma in HIV-uninfected patients. The study, published in ...
ASCO Publishes New Conflict of Interest Policy
ASCO has released its new conflict of interest policy, ASCO Policy for Relationships With Companies, which updates its earlier policy in key ways that are designed to increase transparency in relationships with commercial interests. Comprehensive Framework The new policy establishes a more...
Joseph A. Sparano, MD, Named Vice Chair of ECOG-ACRIN Cancer Research Group
The Eastern Cooperative Oncology Group and the American College of Radiology Imaging Network (ECOG-ACRIN) Cancer Research Group recently announced that it has appointed Joseph A. Sparano, MD, as its Vice Chair. In his new role, Dr. Sparano will assist the Group leadership in defining research...
Determining the Best Diet for Patients with Cancer
How much does diet and body weight influence the effectiveness of cancer treatment and reduce the risk of cancer recurrence? What is the optimal diet for patients with cancer and survivors to follow? There are currently no hard and fast rules, but some dietary clues are starting to emerge. Search...
A New Center for Lymphoid Malignancies Aims to Provide Precision Patient Care
In January, New York-Presbyterian Hospital/Columbia University Medical Center opened the Center for Lymphoid Malignancies, a 3,700 square foot outpatient clinic, in the heart of Midtown Manhattan. The Center is solely focused on the treatment of all forms of Hodgkin and non-Hodgkin lymphoma,...
Postinduction Dexamethasone and Individualized Dosing of Asparaginase Improve Outcome in Pediatric ALL
Findings from the Dana-Farber Cancer Institute ALL Consortium Protocol 00-01, recently reported by Lynda M. Vrooman, MD, Dana-Farber Cancer Institute, and colleagues in Journal of Clinical Oncology, indicate that postinduction dexamethasone and individualized dosing of Escherichia coli–derived...
Cancer Organizations Recognize Sen. Shelby and Rep. DeLauro for Their Commitment to the Fight against Cancer
Sen. Richard Shelby (R-AL) and Rep. Rosa DeLauro (D-CT) were recognized recently by the American Society of Clinical Oncology, the American Association for Cancer Research, the Association of American Cancer Institutes, and Friends of Cancer Research for their outstanding commitment to cancer...
Death with Dignity Program at Seattle Cancer Care Alliance
After passage of the Washington Death with Dignity Act in November 2008, the Seattle Cancer Care Alliance—the site of outpatient care for patients with cancer from Fred Hutchinson–University of Washington Cancer Consortium—developed a Death with Dignity program. The program is adapted from existing ...
Impressive Results Shown for Immune Checkpoint Inhibitors: Anti-PD1 and Anti-PD-L1 Antibodies
Antibody-mediated blockade of the programmed death 1 protein (PD-1) and its ligand (PD-L1) resulted in potent and durable tumor regression and prolonged stabilization of disease in patients with advanced solid tumors, according to early data on these drugs presented at the 2013 ASCO Annual Meeting. ...
SIDEBAR: Understanding the PD-1/PD-L1 Pathway and Its Promise
Tumors can be recognized by the immune system, but they have multiple mechanisms for evading eradication by the immune system. The tumor microenvironment suppresses the immune response, partly because tumors can express molecules that inhibit immune responses. The cancer clinical trials summarized...
Innovative Leader in Oncology Is Committed to Tackling the Most Critical Issues in Managed Care
“I’m a Nebraskan,” said Lee N. Newcomer, MD, MHA, a leader in the oncology community who is well known for his innovative efforts to align physician payment and quality of care in ways that will best configure to the rapidly changing health-care environment. Speaking in the flat vowels and neutral...
UICC President Balances Innovation and Pragmatism to Reduce the Global Burden of Cancer
Mary K. Gospodarowicz, MD, FRCPC, is determined to help reduce the worldwide burden of cancer, a problem of epic proportions. Her approach is simple: adopt what works and reject what doesn’t. Much progress in the fight against cancer can be made without waiting for the next paradigm-changing...
Pioneering Oncologist's Research on Cisplatin Revolutionized Testicular Cancer Treatment
Lawrence H. Einhorn, MD, grew up in Dayton, Ohio, in a time and place that he describes as pleasant and community-oriented. Throughout his distinguished career, Dr. Einhorn has maintained strong roots in the Midwest. “After finishing high school, I did my undergrad at Indiana University and went to ...
After a Distinguished Career, Trailblazing Swiss Oncologist Remains Devoted to Addressing the Global Cancer Challenge
Switzerland, a landlocked country with a population about that of New York City, has four geographic regions, each with its own official language. Internationally regarded lymphoma and breast cancer expert, Franco Cavalli, MD, FRCP, was born and raised in Locarno, a town in the Italian region of...
Prolific Surgical Oncologist Understands the True Value of Mentorship
Charles M. Balch, MD, FACS, PhD (hc), was born in Milford, Delaware, where his father was a research chemist for DuPont during World War II. “My father was part of the team that developed rayon for parachutes. It was a top priority program because they couldn’t get nylon from the Philippines. After ...
Emil 'Tom' Frei III, MD 1924–2013
The pages of medical history are dog-eared with breakthroughs that have transformed medicine and saved lives. One of those dog-eared pages belongs to Emil Frei III, MD, known to his colleagues and friends as Tom. In the dawn of oncology, Dr. Frei, along with his associate, Emil Freireich, MD, did...
FDA Clears Multicenter Trial of Treatment for Hair Loss Related to Chemotherapy
The FDA has approved initiation of a multicenter trial of the DigniCap System, a scalp-cooling device for chemotherapy-related hair loss. The trial is the second and final phase of study for the DigniCap System. A pilot study previously conducted by researchers at the University of California San...
Angelina Jolie's Disclosure of Prophylactic Bilateral Mastectomy: A Positive Example for Women with BRCA Mutations?
Angelina Jolie, in a New York Times article entitled “My Medical Choice,”1 disclosed that having a BRCA1 mutation and an estimated 87% risk of breast cancer, “I decided to be proactive and minimize the risk as much I could. I made a decision to have a preventive double mastectomy.” She was writing...
Focus on the Georgia Society of Clinical Oncology
With a roster of over 600 members that includes community and institutional oncologists, administrators, registered nurses, and patient navigators, the Georgia Society of Clinical Oncology (GASCO) is one of ASCO’s largest State Affiliates. Founded in 1986, the Atlanta-based Society is active in...
Vitamin D and Cancer: A Uniform Dose Is Unlikely to Fit All Patients
Integrative Oncology is guest edited by Barrie R. Cassileth, MS, PhD, Chief of the Integrative Medicine Service and Laurance S. Rockefeller Chair in Integrative Medicine at Memorial Sloan-Kettering Cancer Center, New York. The Integrative Medicine Service at Memorial Sloan-Kettering Cancer Center...
Improving Treatment and Care for Patients with Primary Brain Cancers
Despite advances in neuroimaging, the development of focused radiation therapy, and more effective chemotherapy, life expectancy for patients with primary malignant tumors of the brain and spinal cord remains stubbornly low at between 15 and 18 months. However, there are significant advances on the ...
